Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01.

Abstract:

:Vesicular stomatitis virus (VSV) has been extensively utilized as a viral vector system for the induction of protective immune responses against a variety of pathogens. We constructed recombinant VSVs specifying either the Indiana or Chandipura virus G glycoprotein and expressing the West Nile virus (WNV) envelope (E) glycoprotein. Mice were intranasally vaccinated using a prime (Indiana)-boost (Chandipura) immunization approach and challenged with the virulent WNV-LSU-AR01. Ninety-percent (9 of 10) of the vaccinated mice survived as compared to 10% of the mock-vaccinated mice after WNV lethal challenge. Histopathological examination of brain tissues revealed neuronal necrosis in mock-vaccinated mice but not in vaccinated mice, and vaccinated, but not mock-vaccinated mice developed a strong neutralizing antibody response against WNV. Extensive immunological analysis using polychromatic flow cytometry staining revealed that vaccinated, but not mock-vaccinated mice developed robust cellular immune responses as evidenced by up-regulation of CD4(+) CD154(+) IFNgamma(+) T cells in vaccinated, but not mock-vaccinated mice. Similarly, vaccinated mice developed robust E-glycoprotein-specific CD8(+) T cell immune responses as evidenced by the presence of a high percentage of CD8(+) CD62L(low) IFNgamma(+) cells. In addition, a sizeable population of CD8(+) CD69(+) cells was detected indicating E-specific activation of mature T cells and CD4(+) CD25(+) CD127(low) T regulatory (T reg) cells were down-regulated. These results suggest that VSV-vectored vaccines administered intranasally can efficiently induce protective humoral and cellular immune responses against WNV infections.

journal_name

Vaccine

journal_title

Vaccine

authors

Iyer AV,Pahar B,Boudreaux MJ,Wakamatsu N,Roy AF,Chouljenko VN,Baghian A,Apetrei C,Marx PA,Kousoulas KG

doi

10.1016/j.vaccine.2008.11.087

subject

Has Abstract

pub_date

2009-02-05 00:00:00

pages

893-903

issue

6

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(08)01635-6

journal_volume

27

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults.

    abstract::A formalin-inactivated aluminium hydroxide adsorbed hepatitis A vaccine was evaluated in a dose-response study on 195 healthy male adults (age range: 18-31 years) in two French hospitals (Lyon, Rouen). Four doses (20, 40, 80, 160 RIA antigen units) were administered intramuscularly (i.m.) in two injections over a 6-mo...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/0264-410x(95)93140-5

    authors: Garin D,Vidor E,Wallon M,Fanget B,Brasseur P,Delolme H,Caron F,Mojon M,Gravey A,Humbert G

    更新日期:1995-02-01 00:00:00

  • Development of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens.

    abstract::The objective of the present study was to investigate the feasibility of a subunit vaccine and a live bacteria vaccine to protect chickens against infectious bursal disease virus (IBDV) infection. The gene for VP2 of a new wild-type very virulent IBDV (vvIBDV) strain was cloned into an Escherichia coli expression syst...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.05.015

    authors: Rong J,Cheng T,Liu X,Jiang T,Gu H,Zou G

    更新日期:2005-09-23 00:00:00

  • Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs.

    abstract::Evidence that influenza vaccination during pregnancy is safe and effective at preventing influenza disease in women and their children through the first months of life is increasing. Several reports of reduced risk of adverse outcomes associated with influenza vaccination have generated interest in its potential for i...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.08.041

    authors: Savitz DA,Fell DB,Ortiz JR,Bhat N

    更新日期:2015-11-25 00:00:00

  • A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.

    abstract:BACKGROUND:This phase I trial evaluated the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost, previously demonstrated to be protective in animal studies, in healthy UK adults. METHODS:We enrolled 42 healthy, BCG-vaccinated adults into 4 groups: low dose Starter ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.10.102

    authors: Wilkie M,Satti I,Minhinnick A,Harris S,Riste M,Ramon RL,Sheehan S,Thomas ZM,Wright D,Stockdale L,Hamidi A,O'Shea MK,Dwivedi K,Behrens HM,Davenne T,Morton J,Vermaak S,Lawrie A,Moss P,McShane H

    更新日期:2020-01-22 00:00:00

  • The Hitchner B1 strain of Newcastle disease virus induces high levels of IgA, IgG and IgM in newly hatched chicks.

    abstract::Reaseheath line C chicks produced IgA, IgG and IgM in their serum, tears, spleen and Harderian gland (HG) as a consequence of oculotopical vaccination with the Hitchner B1 strain of Newcastle disease virus. The IgM response was seen first, at 5 days after vaccination, and antiviral IgM levels in the tears and serum we...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(95)80012-3

    authors: Russell PH,Ezeifeka GO

    更新日期:1995-01-01 00:00:00

  • Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.

    abstract::Chagas' disease is a major tropical disease for which a cure for chronic phase does not exist yet. Trypanosoma cruzi trans-sialidase (TS) seems to be involved in relevant processes such as infectivity, host survival and, very importantly, disease pathogenesis. In this study, we show that mice vaccinated with an engine...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.02.060

    authors: Fontanella GH,De Vusser K,Laroy W,Daurelio L,Nocito AL,Revelli S,Contreras R

    更新日期:2008-05-02 00:00:00

  • A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.

    abstract::Forty-four adult patients with cutaneous leishmaniasis (CL) were enrolled in a randomized, double-blind, controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 ant...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2010.07.063

    authors: Nascimento E,Fernandes DF,Vieira EP,Campos-Neto A,Ashman JA,Alves FP,Coler RN,Bogatzki LY,Kahn SJ,Beckmann AM,Pine SO,Cowgill KD,Reed SG,Piazza FM

    更新日期:2010-09-14 00:00:00

  • Hepatitis A shifting epidemiology in Latin America.

    abstract::In the past, Latin America was considered to be an area of high endemicity for hepatitis A virus (HAV) infection, with most people infected in early childhood. A seroepidemiological study was recently undertaken in six countries to determine whether this pattern has changed. The highest seroprevalence of antibodies to...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00466-1

    authors: Tanaka J

    更新日期:2000-02-18 00:00:00

  • The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae.

    abstract::Potential vaccine strategies against otitis media are to prevent (1) symptomatic infections in the middle ear and/or (2) carriage of pneumococci and thereby subsequent middle ear infections. The possibility of using immunity to virulence proteins of pneumococci to elicit immunity against pneumococci has been examined....

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(00)00285-1

    authors: Briles DE,Hollingshead SK,Nabors GS,Paton JC,Brooks-Walter A

    更新日期:2000-12-08 00:00:00

  • Placebo-controlled efficacy study of hepatitis A vaccine in Valdivia, Chile.

    abstract::A placebo-controlled, double-blind study on the efficacy of a hepatitis A vaccine (SmithKline Beecham Biologicals) was started in a region of Chile in September 1990, using hepatitis B vaccine as control. A total of 260 healthy children, 6-15 years of age, negative for antibody to hepatitis A virus (anti-HAV), antibod...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0264-410x(92)90573-3

    authors: Riedemann S,Reinhardt G,Frösner GG,Ibarra H,Moraleda L,Hering V,Siegel F,Toledo C,Leon J,Gonzalez JL

    更新日期:1992-01-01 00:00:00

  • Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immunostimulating complex (ISCOM).

    abstract::Immunostimulating complexes (ISCOMs) are subunit vaccines that are particularly effective in producing immunity against systemic viral infections, but their effectiveness against mucosal infections has received little attention. To study their ability to produce mucosal immune responses in the female reproductive trac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(91)90269-c

    authors: Thapar MA,Parr EL,Bozzola JJ,Parr MB

    更新日期:1991-02-01 00:00:00

  • Advancing a vaccine to prevent hookworm disease and anemia.

    abstract::A human hookworm vaccine is under development and in clinical trials in Africa and the Americas. The vaccine contains the Na-APR-1 and Na-GST-1 antigens. It elicits neutralizing antibodies that interfere with establishment of the adult hookworm in the gut and the ability of the parasite to feed on blood. The vaccine t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.03.078

    authors: Hotez PJ,Beaumier CM,Gillespie PM,Strych U,Hayward T,Bottazzi ME

    更新日期:2016-06-03 00:00:00

  • Frequency and erroneous usage of temporary medical exemptions and knowledge of immunization guidelines among some Miami-Dade County Florida providers.

    abstract:OBJECTIVE:We assessed knowledge and practices regarding immunization guidelines and the Florida Certificate of Immunization (DH-680) based on FL-DOH and CDC recommendations, to identify the cause of the increasing number of erroneously issued temporary medical exemptions (TME) among selected health care providers in Mi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.041

    authors: Cruze AR,Zhang G,Thomas L,Alonso J,Sandoval L

    更新日期:2014-07-31 00:00:00

  • Use of protamine sulphate for elimination of substrate DNA in poliovaccines produced on continuous cell lines.

    abstract::Cell substrate DNA was shown to be an abundant contaminant in the clarified preparations of the Sabin type 1, 2 and 3 poliovaccines produced on a continuous cell line (4647). The size of the DNA, as evaluated for the Sabin type 1 poliovaccine, was highly heterogeneous, ranging from 100 to 20,000 base pairs. In view of...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(91)90156-z

    authors: Amosenko FA,Svitkin YV,Popova VD,Terletskaya EN,Timofeev AV,Elbert LB,Lashkevich VA,Drozdov SG

    更新日期:1991-03-01 00:00:00

  • Reduction of disulfide bonds in Plasmodium falciparum gp195 abolishes the production of growth-inhibitory antibodies.

    abstract::The role of disulfide-dependent protein conformation of the 195,000 kDa Plasmodium falciparum merozoite surface glycoprotein in the induction of biologically active antibodies was investigated. Serum samples from rabbits immunized with native gp195 had a mean ELISA titre of 1/560,000 and a mean in vitro parasite growt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90072-6

    authors: Locher CP,Tam LQ

    更新日期:1993-01-01 00:00:00

  • A vero cell derived combined vaccine against sheep pox and Peste des Petits ruminants for sheep.

    abstract::The combined sheep pox and Peste des Petits ruminants (PPR) vaccine was prepared in lyophilized form containing recommended doses of both vaccine viruses. Safety and immunogenicity of this combined vaccine was evaluated in sheep. Sheep immunized subcutaneously with 1ml of live attenuated vaccine consisting of 10(3)TCI...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.104

    authors: Chaudhary SS,Pandey KD,Singh RP,Verma PC,Gupta PK

    更新日期:2009-04-28 00:00:00

  • Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.

    abstract::Because of the serious economic and medical consequences of brucellosis, efforts are to prevent infection of domestic animals through vaccines. Many disadvantages are associated with the current Brucella melitensis Rev.1 vaccine prompting development of alternative vaccines and delivery. Escherichia coli (DH5α) was en...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.04.036

    authors: Gupta VK,Radhakrishnan G,Harms J,Splitter G

    更新日期:2012-06-08 00:00:00

  • PIPDeploy: Development and implementation of a gamified table top simulation exercise to strengthen national pandemic vaccine preparedness and readiness.

    abstract::Successful emergency vaccination campaigns rely on effective deployment and vaccination plans. This applies to localised outbreaks as well as for pandemics. In the wake of the 2009 H1N1 influenza pandemic, analysis of the global Vaccine Deployment Initiative, through which the World Health Organization (WHO) donated p...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.11.047

    authors: Ghiga I,Richardson S,Álvarez AMR,Kato M,Naidoo D,Otsu S,Nguyen PT,Nguyen PN,Nguyen T

    更新日期:2021-01-08 00:00:00

  • Development of a Rift Valley fever virus viremia challenge model in sheep and goats.

    abstract::Rift Valley fever virus (RVFV), a member of the family Bunyaviridae, causes severe to fatal disease in newborn ruminants, as well as abortions in pregnant animals; both preventable by vaccination. Availability of a challenge model is a pre-requisite for vaccine efficacy trials. Several modes of inoculation with RVFV Z...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.02.066

    authors: Weingartl HM,Miller M,Nfon C,Wilson WC

    更新日期:2014-04-25 00:00:00

  • Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

    abstract:BACKGROUND:Gram-negative bacteria (GNB) are a leading cause of nosocomial infection and sepsis. Increasing multi-antibiotic resistance has left clinicians with fewer therapeutic options. Antibodies to GNB lipopolysaccharide (LPS, or endotoxin) have reduced morbidity and mortality as a result of infection and are not su...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.10.072

    authors: Cross AS,Greenberg N,Billington M,Zhang L,DeFilippi C,May RC,Bajwa KK

    更新日期:2015-11-27 00:00:00

  • Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.

    abstract:PURPOSE:Meningococcal C conjugate vaccine was included in December 2000 in the Spanish childhood vaccination at 2, 4 and 6 months of age. In 2006, routine vaccination was modified to two doses at 2 and 4-6 months and a booster dose during the second year of age. Additionally, successive catch-up campaigns were launched...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.03.010

    authors: Garrido-Estepa M,León-Gómez I,Herruzo R,Cano R

    更新日期:2014-05-07 00:00:00

  • Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety.

    abstract::There is an ongoing need for new adjuvants to facilitate development of vaccines against HIV, tuberculosis, malaria and cancer, amongst many others. Unfortunately, the most potent adjuvants are often associated with toxicity and safety issues. Inulin, a plant-derived polysaccharide, has no immunological activity in it...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.09.030

    authors: Petrovsky N,Cooper PD

    更新日期:2015-11-04 00:00:00

  • Factors underlying suboptimal childhood immunisation.

    abstract::This review considers possible reasons behind parents' missed vaccination opportunities in the context of the latest immunisation coverage rates for England. Suboptimal uptake is not exclusive to measles, mumps and rubella (MMR). A substantial proportion of children also miss diphtheria, tetanus and polio vaccination....

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2006.06.060

    authors: Tickner S,Leman PJ,Woodcock A

    更新日期:2006-11-30 00:00:00

  • Measurement of Clostridium perfringens beta-toxin production by surface plasmon resonance immunoassay.

    abstract::A rapid and sensitive assay using surface plasmon resonance (SPR) immunoassay has been developed for the detection of Clostridium perfringens beta-toxin. The SPR immunoassay was conducted off-line by passing fermentation broth by a sensor chip coated with a monoclonal antibody specific for C. perfringens beta-toxin. Q...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(97)00282-x

    authors: Hsieh HV,Stewart B,Hauer P,Haaland P,Campbell R

    更新日期:1998-05-01 00:00:00

  • A nationwide vaccination programme in Italy against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.

    abstract::In order to prevent hepatitis B virus (HBV) infection of infants of hepatitis B surface antigen (HBsAg)-positive mothers, a nation-wide immunization programme was initiated in Italy in January 1984. During the first 3 years (1984-86), 651,667 out of 1726,000 pregnant women (37.8%) were screened for HBsAg; the percenta...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(89)90056-x

    authors: Stroffolini T,Pasquini P,Mele A

    更新日期:1989-04-01 00:00:00

  • Interpretation of primary care physicians' attitude regarding rotavirus immunisation using diffusion of innovation theories.

    abstract::To evaluate primary care physicians' attitude towards implementation of rotavirus (RV) immunisation into the Swiss immunisation schedule, an eight-question internet-based questionnaire was sent to the 3799 subscribers of InfoVac, a nationwide web-based expert network on immunisation issues, which reaches >95% of paedi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.05.097

    authors: Agyeman P,Desgrandchamps D,Vaudaux B,Berger C,Diana A,Heininger U,Siegrist CA,Aebi C

    更新日期:2009-07-30 00:00:00

  • Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).

    abstract::The hepatitis E virus (HEV) vaccine, Hecolin(®), was licensed in China for the prevention of HEV infection and HEV-related diseases with demonstrated safety and efficacy [1,2]. The vaccine is composed of a truncated HEV capsid protein, p239, as the sole antigen encoded by open reading frame 2 and produced using Escher...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.05.064

    authors: Zhang X,Wei M,Pan H,Lin Z,Wang K,Weng Z,Zhu Y,Xin L,Zhang J,Li S,Xia N,Zhao Q

    更新日期:2014-07-07 00:00:00

  • Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.

    abstract::A number of challenges for developing a protective pre-pandemic influenza A vaccine exists including predicting the target influenza strain and designing the vaccine for an immunologically naïve population. Manufacturing and supply of the vaccine would also require implementing ways to increase coverage for the larges...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.07.107

    authors: Allen JD,Owino SO,Carter DM,Crevar CJ,Reese VA,Fox CB,Coler RN,Reed SG,Baldwin SL,Ross TM

    更新日期:2017-09-12 00:00:00

  • Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model.

    abstract::Schistosomiasis is an important parasitic disease for which there is no available vaccine. We have focused on a functionally important antigen of Schistosoma mansoni, Sm-p80, as a vaccine candidate because of its consistent immunogenicity, protective potential and antifecundity effect observed in murine models; and fo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.02.096

    authors: Ahmad G,Zhang W,Torben W,Damian RT,Wolf RF,White GL,Chavez-Suarez M,Kennedy RC,Siddiqui AA

    更新日期:2009-05-11 00:00:00

  • Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.

    abstract::A synthetic T cell immunogen (TCI) has been designed as a candidate DNA-based vaccine against Human immunodeficiency virus (HIV)-1 using cytotoxic T lymphocytes (CD8(+) CTL) and T-helper lymphocytes (CD4(+) Th) epitopes retrieved from the Los Alamos HIV Molecular Immunology Database. The protein 392 amino acids in len...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.09.048

    authors: Bazhan SI,Belavin PA,Seregin SV,Danilyuk NK,Babkina IN,Karpenko LI,Nekrasova NA,Lebedev LR,Ignatyev GM,Agafonov AP,Poryvaeva VA,Aborneva IV,Ilyichev AA

    更新日期:2004-04-16 00:00:00